CQDM and Brain Canada join forces again in the funding of two new research projects to address unmet needs in brain research CQDM and Brain Canada are proud to announce the funding of two new multi-disciplinary and multi-institutional research projects under the second edition of their Focus on Brain strategic initiative. The partners will award a total of $3M to two research teams to develop cutting-edge tools, technologies and platforms designed to accelerate the discovery of new drugs for brain and nervous system disorders.
A team of scientists led by Dr. Michel Desjardins from the University of Montreal and Dr. Heidi McBride from the Montreal Neurological Institute and Hospital (MNI) at McGill University have discovered that two genes associated with Parkinson's disease (PD) are key regulators of the immune system, providing direct evidence linking Parkinson's to autoimmune disease. Using both cellular and mouse models, the team has shown that proteins produced by the two genes, known as PINK1 and Parkin, are required to prevent cells from being detected and attacked by the immune system.
The results of their study, published in the journal Movement Disorders, could also have a major impact on the quality of research on Parkinson’s disease.
Millions of Canadians are affected by diseases of the brain such as ALS, Parkinson’s and brain tumours, for which there are limited treatments and no cures. By 2020, neurological conditions will become the leading cause of death and disability.
The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, is at the forefront of Parkinson’s research and clinical care. Parkinson’s patients are seen at The Neuro’s Movement Disorders Clinic and the Montreal General Hospital. Approximately 100,000 Canadians have Parkinson’s disease. The Neuro to introduce experimental drug treatment
The Montreal Neurological Institute and Hospital - The Neuro, McGill University and the McGill University Health Centre, is at the forefront of Parkinson’s research and clinical care. Parkinson’s patients are seen at The Neuro’s Movement Disorders Clinic and the Montreal General Hospital. Approximately 100,000 Canadians have Parkinson’s disease. New Rapid-Access Clinic at The Neuro reduces wait time
Scientists from the Montreal Neurological Institute and Hospital in Canada have discovered that two genes linked to hereditary Parkinson’s disease are involved in the early-stage quality control of mitochondria. The protective mechanism, which is reported in The EMBO Journal, removes damaged proteins that arise from oxidative stress from mitochondria.
Research opens door to new drug therapies for Parkinson’s disease McGill University researchers have unlocked a new door to developing drugs to slow the progression of Parkinson’s disease. Collaborating teams led by Dr. Edward A. Fon at the Montreal Neurological Institute and Hospital -The Neuro, and Dr. Kalle Gehring in the Department of Biochemistry at the Faculty of Medicine, have discovered the three-dimensional structure of the protein Parkin.
What is Parkinson’s Disease? Parkinson’s disease is a neurological condition related to the death of specific brain cells that produce dopamine, a chemical needed for brain cells to control muscular movement. In Parkinson’s disease, dopamine-producing cells stop functioning for reasons still unknown.
November 27, 2012 - Clinician-scientists take a unique, integrated approach that is essential to advancing science and medicine. Problems encountered in the clinic inspire research and new findings from the labs are directly applied to patients’ needs. The integrated model is a hallmark of the Montreal Neurological Institute and Hospital – The Neuro, at McGill University and the MUHC and is now being replicated worldwide.
International study with researchers at The Neuro reveals links with other neurodegenerative diseases MONTREAL, October 9, 2012 - Scientists at the Montreal Neurological Institute and Hospital – The Neuro, McGill University working with a team at Oxford University have uncovered the genetic defect underlying a group of rare genetic disorders. Using a new technique that has revolutionized genetic studies, the teams determined that mutations in the RMND1 gene were responsible for severe neurodegenerative disorders, in two infants, ultimately leading to thei